HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Lisdexamfetamine Dimesylate

HCID 11597697
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
608137-33-3
Standard SMILES
CS(=O)(=O)O.CS(=O)(=O)O.C[C@@H](Cc1ccccc1)NC(=O)[C@@H](N)CCCCN
InChIKey
CETWSOHVEGTIBR-FORAGAHYSA-N
Molecular formula
C17H33N3O7S2
Average molar mass
455.6 g/mol
Monoisotopic mass
455.17599275

Overview

Lisdexamfetamine Dimesylate is the dimesylate form and prodrug of the d-isomer of amphetamine, a non-catecholamine sympathomimetic amine with central nervous system (CNS) stimulating activity. Upon administration, lisdexamphetamine is converted to dextroamphetamine through cleavage of the lysine group. Dextroamphetamine acts by facilitating the release of catecholamines, particularly noradrenaline and dopamine, from its storage sites in nerve terminals in the CNS, and inhibits their uptake within the mesocorticolimbic system, a major component of the brain reward system, resulting in measurable behavioral changes such as euphoria, mental alertness and excitement and appetite suppression. As a CNS stimulant, this agent may increase blood pressure.

Names & identifiers

Preferred name
Lisdexamfetamine Dimesylate
IUPAC
(2S)-2,6-diamino-N-[(2S)-1-phenylpropan-2-yl]hexanamide;methanesulfonic acid
English name
(2S)-2,6-Diamino-N-[(1S)-1-methyl-2-phenylethyl]hexanamide dimethanesulfonate
Molecular formula
C16H29N3O4S
Molecular weight
359.49

Names & synonyms

Lisdexamfetamine dimesylateVyvanse608137-33-3Lisdexamfetamine mesilateNRP-104SPD489Tyvenselis-dexamfetamine dimesylateNRP104SJT761GEGSNRP 104SPD-489
Show more names
LdxLisdexamfetamine mesylateLisdexamphetamine-DimesylateSpd 489Lisdexamfetamine (mesylate) (CRM)
Lisdexamfetamine dimesilateLisdexamphetamine dimesilateLisdexamfetamine dimethanesulfonateDTXSID60209653Dimesylate, Lis-dexamfetamineelvanseElvanse adultRefChem:57033

Database identifiers

CAS
608137-33-3
PubChem CID
11597697
DTXSID
DTXSID60209653
ChEMBL
CHEMBL1201178
UNII
SJT761GEGS

Properties

Computed structural properties

Topological polar surface area
207 Ų
Hydrogen bond donors
5
Hydrogen bond acceptors
9
Rotatable bonds
8
Heavy atoms
29
Formal charge
0
Complexity
344

Experimental & physicochemical properties

DrugsDEA NFLIS-Drug Category -> Phenethylamines (Amphetamines) (S)
Human Drugs · 3 items

Breast Feeding; Lactation; Milk, Human; Adrenergic Agents; Central Nervous System Stimulants; Dopamine Agents; Sympathomimetics; Wakefulness-Promoting Agents

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Physicochemical properties

Flash point
9 ℃ · 9℃
storage temp.
-20 °C · -20°C
form
A neat solid
FDA UNII
761 GEGS · SJT761GEGS
NCI Drug Dictionary
lisdexamfetamine dimesylate
Symbol(GHS)
2 · GHS02,GHS06,GHS08
Signal word
Danger
Hazard statements
225 · H225-H301+H311+H331-H370
Precautionary statements
210 · P210-P260-P280-P301+P310-P311
Hazard Codes

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

Toxicology

Drug Induced Liver Injury · 6 items

Drug Induced Liver Injury Rank (DILIrank 2.0)

Lisdexamfetamine dimesylate

Ambiguous-DILI-concern

3

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Safety data

wgk
1
ridadr
UN1230 - class 3 - PG 2 - Methanol, solution
risk_code
11-23/24/25-39/23/24/25
Signal word
Danger
Symbol(GHS)
GHS02,GHS06,GHS08
hazard_code
F,T
safety_code
7-16-36/37-45
Hazard statements
H225-H301+H311+H331-H370
Precautionary statements
P210-P260-P280-P301+P310-P311

Chemistry & industry

Pharmacology

FDA Pharmacological Classification · 4 items

LISDEXAMFETAMINE DIMESYLATE

Central Nervous System Stimulation [PE]; Central Nervous System Stimulant [EPC]

LISDEXAMFETAMINE DIMESYLATE CAPSULES

Central Nervous System Stimulant [EPC]; Central Nervous System Stimulation [PE]

MeSH Pharmacological Classification · 2 items

A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here.

Drugs that block the transport of DOPAMINE into axon terminals or into storage vesicles within terminals. Most of the ADRENERGIC UPTAKE INHIBITORS also inhibit dopamine uptake.

Applications · 3 items

DescriptionADHD is a neurobehavioral disorder characterized by varying degrees of inattention, hyperactivity, and impulsivity. ADHD is typically diagnosed in childhood and affects 7–12% of the pediatric population in the United States with the condition often enduring into adulthood. While the precise mechanism of action of lisdexamfetamine in treating ADHD is not known, amphetamines are believed to inhibit the reuptake of the neurotransmitters dopamine and noradrenaline (norepinephrine), thereby increasing their presynaptic availability and release into extraneuronal space. The prodrug is constructed by the condensation of D-amphetamine with the activated ester (N-hydroxysuccinimide) of bis-tert-butoxycarbonylprotected L-lysine. Lisdexamfetamine is ultimately generated by treatment with hydrochloric acid in dioxane. The most common adverse events, comparable to other amphetamine formulations, were decreased appetite, insomnia, upper abdominal pain, and irritability. Lisdexamfetamine is contraindicated in patients with advanced arteriosclerosis, symptomatic cardiovascular disease, moderate-to-severe hypertension, hyperthyroidism, known hypersensitivity to the sympathomimetic amines, glaucoma, a predisposition to agitated states, and a history of drug abuse. In addition, the drug should not be administered during or within 14 days of treatment with monoamine oxidase inhibitors. It has also been noted that psychostimulants may exacerbate symptoms of pre-existing psychotic disorders, so caution and close observation are recommended in this patient population.

Related reactions

15 records
New reaction record
HRID 643241 reaction equation
HRID 643241As product
HRID 1441220 reaction equation
HRID 1441220As product
HRID 1442488 reaction equation
HRID 1442488As product
HRID 1442489 reaction equation
HRID 1442489As product
HRID 1443641 reaction equation
HRID 1443641As product
HRID 2234738 reaction equation
HRID 2234738As product
HRID 2237362 reaction equation
HRID 2237362As product
HRID 2239227 reaction equation
HRID 2239227As product
PreviousPage 1 of 2

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
F,T
Risk Statements
11 · 11-23/24/25-39/23/24/25
Safety Statements
7 · 7-16-36/37-45
RIDADR
1230 · UN1230 - class 3 - PG 2 - Methanol, solution
WGK Germany
1 · 1

DescriptionLisdexamfetamine (mesylate) (Item No. 18050) is an analytical reference material categorized as an amphetamine. Its chemical structure consists of D-amphetamine (Item Nos. 14204 | 15650) coupled with the essential amino acid L-lysine. Lisdexamfetamine is an inactive prodrug that is converted to D-amphetamine upon cleavage of the lysine via enzymatic hydrolysis in red blood cells. Lisdexamfetamine is regulated as a Schedule II compound in the United States. This product is intended for research and forensic applications.

UsesTreatment of atten tion deficit hyperactivity disorder (ADHD).